US approves new H1N1 vaccine

US approves new H1N1 vaccine

Washington: The US Food and Drug Administration (FDA) approved the new swine flu vaccine on Tuesday, a long-anticipated step as the American government works to get vaccinations under way next month.

The vaccine is made by CSL Ltd. of Australia; Switzerland’s Novartis; Sanofi-Pasteur of France; and US-based Medimmune, which makes the only nasal-spray flu vaccine.

Health and human services secretary Kathleen Sebelius announced the vaccine’s approval to Congress, and said she hopes to get the first limited supplies distributed early in October.

The bulk of vaccine will start arriving on 15 October, and Sebelius said it should be available at 90,000 sites around the US.

“We will have enough vaccine available for everyone" eventually, Sebelius said everyone who wants it, that is.

The government has ordered 195 million doses for now but may order more if needed, she said. Typically 100 million Americans seek flu vaccine every year.

But the vaccine, which protects against what doctors prefer to call the 2009 H1N1 flu strain, will not arrive all at once. About 45 million doses are expected by mid-October. That is why the government wants the people most likely to catch swine flu, and to suffer complications from it, to be first in line - including children and pregnant women.

FDA licensure means that the government has certified the vaccine is made properly and meets specific manufacturing and quality standards.

Separately, the National Institutes of Health is studying the vaccine dosage and safety. Last week, the NIH announced that one dose appears to protect adults and that protection kicks in eight to 10 days after the shot.